KR20170100039A - 사이토메갈로바이러스 항원 및 이의 용도 - Google Patents

사이토메갈로바이러스 항원 및 이의 용도 Download PDF

Info

Publication number
KR20170100039A
KR20170100039A KR1020177023123A KR20177023123A KR20170100039A KR 20170100039 A KR20170100039 A KR 20170100039A KR 1020177023123 A KR1020177023123 A KR 1020177023123A KR 20177023123 A KR20177023123 A KR 20177023123A KR 20170100039 A KR20170100039 A KR 20170100039A
Authority
KR
South Korea
Prior art keywords
leu
protein
fragment
complex
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177023123A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 카피
클라우디오 시페리
이 싱
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20170100039A publication Critical patent/KR20170100039A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177023123A 2015-01-22 2016-01-22 사이토메갈로바이러스 항원 및 이의 용도 Ceased KR20170100039A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
EP15152221.6 2015-01-22
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Publications (1)

Publication Number Publication Date
KR20170100039A true KR20170100039A (ko) 2017-09-01

Family

ID=52434568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023123A Ceased KR20170100039A (ko) 2015-01-22 2016-01-22 사이토메갈로바이러스 항원 및 이의 용도

Country Status (24)

Country Link
US (2) US10167321B2 (https=)
EP (3) EP3048114A1 (https=)
JP (1) JP6717836B2 (https=)
KR (1) KR20170100039A (https=)
CN (1) CN107531761B (https=)
AU (2) AU2016210548B2 (https=)
BE (1) BE1023087B1 (https=)
BR (1) BR112017015567A2 (https=)
CA (1) CA2974041C (https=)
DK (1) DK3247722T5 (https=)
EA (1) EA038250B1 (https=)
ES (1) ES2937959T3 (https=)
FI (1) FI3247722T3 (https=)
HR (1) HRP20230177T1 (https=)
HU (1) HUE061175T2 (https=)
IL (1) IL253366B (https=)
LT (1) LT3247722T (https=)
MX (1) MX382518B (https=)
PL (1) PL3247722T3 (https=)
PT (1) PT3247722T (https=)
SG (1) SG11201705740UA (https=)
SI (1) SI3247722T1 (https=)
WO (1) WO2016116904A1 (https=)
ZA (1) ZA201704912B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3351636T (pt) * 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR102403547B1 (ko) 2014-07-16 2022-05-30 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
AU2016355468B2 (en) 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11773144B2 (en) 2017-10-02 2023-10-03 Duke University Mosaic HIV-1 envelopes to induce ADCC responses
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
TWI810589B (zh) * 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN118480118B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
PE20141435A1 (es) * 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
MX2015005505A (es) * 2012-10-30 2016-01-08 Redvax Gmbh Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
ES2758505T3 (es) 2013-12-20 2020-05-05 Novartis Ag Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
WO2015092735A1 (en) 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Also Published As

Publication number Publication date
HUE061175T2 (hu) 2023-05-28
US20170369532A1 (en) 2017-12-28
IL253366A0 (en) 2017-09-28
JP6717836B2 (ja) 2020-07-08
PT3247722T (pt) 2023-01-31
US10167321B2 (en) 2019-01-01
DK3247722T5 (da) 2024-10-07
EP3247722A1 (en) 2017-11-29
AU2018226521B2 (en) 2019-10-31
EP4180056A1 (en) 2023-05-17
BE1023087B1 (fr) 2016-11-18
MX382518B (es) 2025-03-13
EA201791562A1 (ru) 2018-04-30
FI3247722T3 (fi) 2023-03-17
AU2016210548B2 (en) 2018-11-08
HRP20230177T1 (hr) 2023-04-14
DK3247722T3 (da) 2023-01-30
BR112017015567A2 (pt) 2018-03-13
CN107531761B (zh) 2022-01-14
IL253366B (en) 2022-03-01
EP3048114A1 (en) 2016-07-27
CA2974041A1 (en) 2016-07-28
LT3247722T (lt) 2023-02-10
SI3247722T1 (sl) 2023-04-28
AU2018226521A1 (en) 2018-09-27
AU2016210548A1 (en) 2017-08-10
CN107531761A (zh) 2018-01-02
JP2018504117A (ja) 2018-02-15
EP3247722B1 (en) 2022-11-30
BE1023087A1 (fr) 2016-11-18
MX2017009538A (es) 2017-11-02
US20190276498A1 (en) 2019-09-12
CA2974041C (en) 2023-04-04
PL3247722T3 (pl) 2023-03-20
ES2937959T3 (es) 2023-04-03
WO2016116904A1 (en) 2016-07-28
EA038250B1 (ru) 2021-07-29
SG11201705740UA (en) 2017-08-30
ZA201704912B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
AU2018226521B2 (en) Cytomegalovirus antigens and uses thereof
EP3230305B1 (en) Cytomegalovirus antigens
CN113151184A (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
EP3047856A1 (en) Cmv antigens and uses thereof
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
HK40087930A (en) Cytomegalovirus antigens and uses thereof
WO2007010399A2 (en) Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections
KR20250024845A (ko) 복제 결함형 헤르페스 심플렉스 바이러스 1형바이러스 백신
US10654899B2 (en) Truncated glycoprotein G of herpes simplex virus 2
CN117062843A (zh) 用于预防感染与治疗长期新冠肺炎的针对SARS-CoV-2变体的疫苗组合物
Ambagala Interference with major histocompatibility complex class I pathway by animal alphaherpesviruses

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170818

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210112

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230525

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231011

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230525

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I